Pfizer's Experimental Obesity Drug Shows Promise Amid Market Challenges

Pfizer announced on February 3, 2026, that its experimental obesity drug, PF-3944, demonstrated significant weight loss in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared to a placebo after 28 weeks. The trial, known as VESPER-3, involved an initial 12-week period of weekly injections followed by a switch to monthly dosing. Notably, no plateau in weight loss was observed, suggesting that patients may continue to lose weight as the study progresses to week 64. The drug is designed as an ultra-long-acting GLP-1 receptor agonist, which allows for less frequent administration than existing treatments.

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trialPfizer tumbles 4% despite beating revenue estimatesPfizer's experimental drug shows up to 12.3% weight loss in mid-stage trialPfizer moves forward with its hopes for a monthly obesity drug

Despite the promising results, Pfizer's stock fell nearly 4% in pre-market trading following the announcement. Investors expressed concerns that the weight loss achieved by PF-3944 may not be sufficient to compete with established market leaders such as Eli Lilly and Novo Nordisk, whose products have shown higher efficacy. The results from the trial, while statistically significant, raised questions about Pfizer's ability to capture market share in a competitive landscape where rivals have already established strong positions.

Pfizer moves forward with its hopes for a monthly obesity drug

Pfizer's Chief Scientific Officer, Chris Boshoff, indicated that modeling predicts a potential weight loss of 16% at week 28 with a higher monthly dose planned for late-stage trials. The company plans to initiate ten phase three trials for PF-3944 this year, focusing on two dosing regimens—a low and medium monthly maintenance dose. Pfizer emphasized that the drug was generally well tolerated, with most side effects reported as mild to moderate.

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trialPfizer's experimental drug shows up to 12.3% weight loss in mid-stage trialPfizer tumbles 4% despite beating revenue estimatesPfizer moves forward with its hopes for a monthly obesity drug

Market analysts noted that the 12.3% weight reduction achieved by PF-3944 falls short of the results reported by competitors. Previous data from an earlier phase 2b study indicated a weight loss of 14.1% after 28 weekly doses, highlighting a discrepancy that could impact investor confidence. Critics argue that Pfizer's ability to penetrate the obesity treatment market may be hindered by these comparative outcomes.

Pfizer tumbles 4% despite beating revenue estimates

While Pfizer reported no new safety issues associated with PF-3944, the trial did see ten participants discontinue treatment due to side effects—five during the weekly phase and five during the monthly phase. This raises questions about the tolerability of the drug, particularly as it moves into larger trials.

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer's foray into the obesity treatment market with PF-3944 shows potential, but the company faces significant challenges in competing against established players. As it prepares for phase three trials, the efficacy of its drug will be closely scrutinized by investors and healthcare professionals alike, particularly in light of the competitive landscape and the mixed reception of its recent trial results.

Pfizer tumbles 4% despite beating revenue estimates